|Bid||12.71 x 1000|
|Ask||13.75 x 1300|
|Day's Range||12.71 - 13.32|
|52 Week Range||9.58 - 18.42|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 30, 2021 - Dec 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.28|
Subscribe to Yahoo Finance Plus to view Fair Value for IMTXLearn more
On average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indicationsTCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof-of-concept for second TCER® molecule IMA402Cash and cash equivalents as well as Other financial assets of $229.1 million1 (€192.8 million) as of June 30, 2021, funding company operations into 2023 Tuebingen, Ger
BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things.